Stagnation in Achieving Recommended Methadone Doses in Opioid Use Disorder Treatment
该研究利用2017和2023年全国调查数据，发现美沙酮治疗项目中达到推荐剂量（≥80毫克/天）的比例停滞在56%-58%，约42%患者剂量不足，表明临床实践与指南存在显著差距。
OBJECTIVE: To assess changes in methadone dosing practices among Opioid Treatment Program (OTP) and evaluate adherence to evidence-based guidelines recommending doses of at least 80 mg/day. STUDY SETTING AND DESIGN: This observational study used a national survey of OTPs to examine longitudinal changes in methadone dosing patterns between 2017 and 2023. Key outcomes included patterns in average dose levels and the relationships between program characteristics and dosing practices. DATA SOURCES AND ANALYTIC SAMPLE: Secondary data were analyzed from national OTP surveys conducted in 2017 and 2023. The sample included programs that provided data on dosing practices and program characteristics. PRINCIPAL FINDINGS: The proportion of OTPs offering the recommended maintenance dose of at least 80 mg/day remained stagnant, moving from 56% in 2017 to 58% in 2023. Concurrently, private-for-profit ownership of programs increased from 36% to 53%. Approximately 42% of patients in 2023 received doses below recommended clinical levels, highlighting a significant misalignment between evidence-based guidelines and actual practice. CONCLUSIONS: National methadone dosing levels stalled between 2017 and 2023. This pattern leaves a significant gap between evidence-based guidelines and clinical practice, which may limit the effectiveness of methadone maintenance treatment. Targeted interventions are needed to identify the systematic factors hindering the adoption of evidence-based care and to maximize treatment success.